

AD _____

Award Number: W81XWH-FE-EG-Á

TITLE: ~~OF~~ ~~W~~ ~~ã~~ ~~˘~~ ~~^~~ ~~Á~~ ~~U~~ ~~]]~~ ~~[~~ ~~l~~ ~~č~~ ~~}~~ ~~ã~~ ~~Á~~ ~~Á~~ ~~•~~ ~~Á~~ ~~@~~ ~~c~~ ~~@~~ ~~!~~ ~~Ö~~ ~~^~~ ~~||~~ ~~Á~~ ~~•~~ ~~ã~~ ~~}~~ ~~Á~~ ~~Á~~ ~~Á~~ ~~^~~ ~~&~~ ~~@~~ ~~ã~~ ~~{~~ ~~Á~~ ~~-~~ ~~Á~~ ~~!~~ ~~^~~ ~~æ~~ ~~ó~~ ~~æ~~ ~~&~~ ~~!~~ ~~Á~~
T ~~^~~ ~~æ~~ ~~æ~~ ~~ã~~

PRINCIPAL INVESTIGATOR: ~~Ö~~ ~~!~~ ~~Ö~~ ~~!~~ ~~^~~ ~~}~~ ~~ã~~ ~~æ~~ ~~U~~ ~~*~~ ~~|~~ ~~^~~

CONTRACTING ORGANIZATION: University of Y ~~ã~~ ~~&~~ ~~}~~ ~~•~~ ~~ã~~
T ~~æ~~ ~~ã~~ ~~[~~ ~~}~~ ~~E~~ ~~Y~~ ~~Q~~ ~~Á~~ ~~H~~ ~~F~~ ~~Í~~ ~~Á~~

REPORT DATE: Ju| ~~^~~ ~~Ö~~ ~~E~~ ~~F~~ ~~G~~ ~~Á~~

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-07-2012		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 1 JUL 2011 - 30 JUN 2012	
4. TITLE AND SUBTITLE A Unique Opportunity to test whether Cell Fusion is a Mechanism of Breast Cancer Metastasis				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-11-1-0205	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Dr. Brenda Ogle E-Mail: ogle@wisc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Wisconsin Madison, WI 53715				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The goal of this proposal is to determine whether cell fusion between tumor cells and hematopoietic cells is the precipitating event for breast cancer metastasis and whether viral fusion proteins enable or catalyze this event. If successful, this discovery would dramatically change our approach to breast cancer therapy in the following specific ways. To date we have completed a significant portion of the tasks delineated in Aim 1. First we have optimized protocols for the separation of myeloid and monocyte populations from human mononuclear cell populations. Also we have optimized electroporation conditions for T47D and human mesenchymal stem cell populations. As a result we have been able to conduct our first co-culture experiments to determine whether breast cancer cells fuse spontaneously with hematopoietic cell types. Preliminary results suggest these populations do fuse spontaneously and that fusion products formed in this way can survive several days and are capable of proliferation. In the upcoming months, combinatorial co-cultures with different blood cell subpopulations (myeloid, lymphoid, and monocyte) and healthy or diseased mammary lines will be performed to determine the frequency of fusion between these subpopulations. The effect of hypoxia and hypoglycemia on the frequency of fusion will also be determined. Identified fusion products will then be purified via flow cytometry and assessed for the capacity to migrate and proliferate.					
15. SUBJECT TERMS None.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 54	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	1
Body.....	1
Key Research Accomplishments.....	3
Reportable Outcomes.....	3
Conclusion.....	3
References.....	NA
Appendices.....	7

INTRODUCTION

Ninety percent of breast cancer-related deaths are due to secondary tumors, or metastases, that form at sites far removed from the primary tumor. Exactly how metastases form is yet unclear. The goal of this proposal is to determine whether cell fusion between tumor cells and hematopoietic cells is the precipitating event for breast cancer metastasis and whether viral fusion proteins enable or catalyze this event. If successful, this discovery would dramatically change our approach to breast cancer therapy in the following specific ways. First, the studies proposed here will help identify fusion partner(s) able to fuse with breast cancer cells to promote a metastatic phenotype. With this information, it may be possible to design strategies to limit interaction with breast cancer cells, including removal of the cell type. In addition, future studies could identify the specific receptor-ligand interactions necessary for cell fusion, to produce a target for drug therapy. Post-fusion events might also be investigated, including the molecular steps governing the integration or rearrangement of genomic DNA to form a single hybrid genome or those steps necessary for activation of genes that regulate the migratory or invasive phenotype. Second, the studies proposed here will investigate the possibility that exogenous, virus-associated proteins might facilitate breast cancer cell fusion. If viral fusogens are found to promote tumor cell fusion, viral vaccination regimes may be appropriate as a prevention strategy. Vaccines might be developed to target viral fusion genes (i.e., fusogens) exclusively, so that the immune system would recognize the protein, even in the context of a eukaryotic cell membrane. Third, the studies proposed here will establish new tools for the study of the complex processes of cell fusion. The inducible bipartite nature of these strategies assures the accurate identification of fusion products, and allows for longitudinal assays both *in vitro* and *in vivo*.

BODY

The research accomplishments made to date relate primarily to Specific Aim 1. Here we reiterate the aim and describe progress on tasks related to the aims as they were delineated in the original statement of work. Of note, the approach has proven successful to this point and so no changes to the original course have been taken or are proposed here.

Specific Aim 1. To determine the specificity and functional capacity of hematopoietic cells that spontaneously fuse with breast cancer cells *in vitro*.

Task 1. Purify hematopoietic subpopulations.

To accomplish Task 1 a VarioMACS separation unit (Part No. 130-043-102) was purchased from Miltenyi Biotec, Inc along with CD33 Microbeads (130-045-501) for the positive selection of blood cells of myeloid lineage and a Pan Monocyte Isolation Kit (130-096-537) for negative selection of classical, non-classical, and intermediate monocytes. Human buffy coat was purchased from Innovative Research (IPLA-WB5) to optimize MACS separation before donor blood samples are obtained. Separation was assessed by 2D flow cytometry analysis using fluorescently conjugated antibodies specific for cell surface markers CD14, CD16 (monocyte markers), and CD33, a myeloid lineage marker. (AbD Serotec). Optimization of the magnetic sorting procedure led to a maximum of 4.8-fold enrichment in myeloid lineage cells and a 3.3-fold enrichment in monocytes when compared to unsorted leukocytes (**Table 1**). Representative flow cytometry charts are included in **Figure 1**. This level of enrichment was

determined to be sufficient for comparison to unsorted leukocytes in future blood cell-cancer cell cocultures.

Task 2 - Optimize lentiviral BiFC transduction parameters for hematopoietic subpopulations.

To accommodate transduction of sensitive cell types to be used in blood cell-cancer cell cocultures such as inactivated monocytes and nontumorigenic mammary epithelial cells, we sought to subclone our BiFC DNA constructs into a lentiviral vector with an RFP reporter. In addition to being gentler on sensitive cells than electroporation, lentiviral transduction can reach high efficiencies (up to 95%) in both adherent and non-adherent cells. This work has been unexpectedly challenging and is ongoing. At present, restriction enzyme sites optimal for ligation into the lentiviral vector have been added 5' and 3' of both BiFC constructs and the constructs have been cloned into temporary TOPO vectors (Invitrogen) for amplification and assessment of restriction enzyme digestion (**Figure 2**).

While lentiviral vectors are under construction, preliminary studies have been conducted by transfecting BiFC vectors using electroporation. Electroporation conditions for T47D transformed mammary epithelial cells were optimized for the purpose of *in vitro* cocultures (**Figure 3**). Over 24 electroporation conditions, the condition of 1 pulse of 1700 V and width of 20 ms was chosen for further experiments, as it gave the highest transduction efficiency (~40% at Day 3) within an acceptable level of cell viability.

Task 4 - Prepare breast cancer cell-hematopoietic subpopulation co-cultures

As a first attempt to discern whether breast cancer cells or normal epithelium can spontaneously fuse with hematopoietic cell types, coculture experiments were carried out using T47D cells and human mesenchymal stem cells (hMSCs). Electroporation conditions for hMSCs had been previously optimized in the lab. Each cell type was transduced with a separate BiFC vector via electroporation. After optimization of seeding densities, preliminary studies showed putative hMSC-T47D fusion products with strong fluorescent signal (**Figure 4A**). The percentage of putative fusion products rose through day 3 of coculture (**Figure 4B**), suggesting that either fusion continued to occur throughout the coculture period or that fusion products gave rise to progeny that retained the BiFC signal. This pattern was replicated in subsequent experiments.

In a separate experiment, the fate of these putative fusion products was tracked over a course of 3 days using time-lapse imaging. Quite interestingly, we found that many putative fusion products were not senescent, but produced progeny and often underwent multipolar divisions (**Figure 3C**).

Unanticipated challenges of the BiFC plasmid

Detection of cell fusion via BiFC depends on a false positive rate of virtually zero, as fusion is a rare event, even *in vitro*. During the course of the co-culture experiments reported above it was determined that cross-contamination of the complementary BiFC plasmids had occurred and

was resulting in high levels of false positives. These false positives took the form of a fluorescent signal in a population of cells transfected with only one of the BiFC plasmids. When the fate of these false positive “control” cells was tracked along with putative fusion products obtained from T47D-hMSC co-cultures, the cell fates were not significantly different (**Figure 4C**). Thus, cells producing a BiFC signal in co-culture experiments to this point can only be labeled “putative” fusion products. This problem is being addressed by purification of the BiFC plasmids through screening of single colonies of *E. coli* transformed with each plasmid, as well as the construction of separate lentiviral vectors.

KEY RESEARCH ACCOMPLISHMENTS

- Optimization of MACS magnetic bead separation of myeloid and monocyte populations from human buffy coat
- Optimization of electroporation transduction conditions for T47D cells
- Indications of possible fusion between T47D and hMSCs in *in vitro* cocultures
- Fate of putative T47DxhMSC fusion products tracked over time; some putative fusion products were found to undergo proliferation

REPORTABLE OUTCOMES

Harkness, TE; Weaver, BA; Alexander, CM; Ogle, BM. Cell Fusion in Tumor Development: Accelerated Genetic Evolution. *Critical Reviews in Oncogenesis*. In Press.

CONCLUSIONS AND FUTURE STUDIES

In the upcoming months we expect to finish construction of lentiviral BiFC vectors and optimize lentiviral transfection with multiple types of blood cells, healthy mammary epithelial cells, and transformed mammary epithelial cells of varying degrees of metastatic capacity. We will work with both human and murine cells in parallel. Combinatorial cocultures with different blood cell subpopulations (myeloid, lymphoid, and monocyte) and healthy or diseased mammary lines will be performed to determine the frequency of fusion between these subpopulations. The effect of hypoxia and hypoglycemia on the frequency of fusion will also be determined. Identified fusion products will then be purified via flow cytometry and assessed by migration and proliferation studies.

In vivo studies will also be initiated using the Cre-Lox luciferase system in murine models of breast cancer. If possible, blood cell fusion partners identified in *in vitro* studies will be selectively transduced with the Cre gene to specify *in vivo* breast cancer fusion products.




Figure 1. Representative flow cytometry plots for MACS blood cell sorting. a) CD33 (myeloid) sorting. Left, unsorted leukocytes. Right, retentate after positive CD33 selection. b) Pan monocyte sorting. Left, unsorted leukocytes. Right, flowthrough after negative selection.

Table 1. Quantification Sorted Hematopoietic Cells using MACS.

	CD33	CD33 +2 rinses	Mon	Mon +2 rinses
Total Sorted	25000000	16500000	30000000	40000000
Post-sorted	1000000	3300000	25243	6332
Theoretical Max	3170000	3192750	1830000	3668000
Actual # Isolated	606300	1561890	2791	3330
% Efficiency	19.13%	48.92%	0.15%	0.09%
% Purity	60.63%	47.33%	11.06%	30.65%
Fold enrichment	4.78	2.45	1.81	3.34




Figure 2. PCR confirmation of ligation of BiFC constructs into TOPO cloning vectors. (-) and (+) indicate negative and positive controls; 1-3 represent three separate bacterial colonies screened after TOPO blunt end cloning and bacterial transformation.




Figure 3. Optimization of electroporation conditions for T47D cells. 150k cells per condition were electroporated with 600 ng of plasmid DNA containing the GFP gene and seeded into one well of a 24 well plate. Cell number shown was collected on Day 3 after electroporation. Electroporation efficiency was calculated as the number of GFP-expressing cells per well divided by the total number of viable cells per well. Conditions were selected to optimize both transduction efficiency and viability.




Figure 4. Probing for fusion events in T47D-hMSC co-cultures. a) Representative image of a co-culture on Day 3. MSCs exhibit a spindle-like morphology while T47D cells appear rounded and elevated from the plate. Putative fusion products fluoresce red. b) Percentage of fusion products in total cell population over a time course of 3 days. Passage number was found to have a significant effect on fusion rate. c) Cell fate over 3 day time lapse imaging. Control cells indicate positive signals tracked from populations receiving only one BiFC plasmid. Experimental cells are putative fusion products tracked in T47D-hMSC cocultures.

Cell Fusion In Tumor Development: Accelerated Genetic Evolution

Ty Harkness^{*}, Beth A. Weaver^{π, +}, Caroline Alexander^{+, ¶} and Brenda M. Ogle^{*, ¶, §}

Departments of Biomedical Engineering^{*}, Cell and Regenerative Biology^π, the Carbone Cancer Center⁺, the Laboratory for Optical and Computational Instrumentation[¶], the Cardiovascular Physiology Core Facility[#], and the Material Sciences Program[§]
University of Wisconsin at Madison, Madison, Wisconsin 53706, USA

Running Title: Impact of Cell Fusion on Cancer

Keywords: metastasis, chromosomal instability, multipolar mitosis, polyploidy, reprogramming

Word Count:

¹ Supported by funding from the Department of Defense BC101200

Address correspondence to:

Brenda Ogle
University of Wisconsin-Madison
2-114 Engineering Centers Building
1550 Engineering Drive
Madison, WI 53706
Phone: 608-265-8267
ogle@wisc.edu

Abstract

The majority of human tumor cells have highly aberrant karyotypes, typically ascribed to errors during tumor cell division, potentially linked to a failure of DNA repair, or telomeric insufficiency. Here we discuss another option, that of cell fusion, which can lead to the reassortment of chromosomes during post-fusion mitosis. The observation of hyperdiploid cells has a long history in cancer genetics, but the concept of cell fusion has been difficult to test in practice. Here, we examine the role of cell fusion during normal development, and relate that to potential cellular fusion partners for primary tumor cells. In particular, we describe the potential for stromal partner fusion during metastatic mobilization. The evidence for genetic and cytoplasmic diversity in heterotypic fusion partners is described, together with the new tools available to help the evaluation of this process as a tumor driver.

Introduction

Cell fusion is an incompletely understood process that occurs spontaneously during normal development as well as in response to viral infection, including infections known to promote transformation, such as HPV.¹ By increasing DNA content as well as centrosome number, cell fusion rapidly alters cellular genotypes and phenotypes and catalyzes genetic diversity. Through stimulating genetic diversity, cell fusion may contribute to the formation, propagation and metastasis of tumor cells. For instance, fusion of a healthy epithelial cell with an activated fibroblast of the local stroma can allow it to acquire the ability to proliferate inappropriately. Fusion of a tumor cell with a mesenchymal stem cell can allow it to degrade extracellular matrix proteins and migrate beyond the basement membrane. Fusion of an epithelial tumor cell with a macrophage could lead to the temporary acquisition of macrophage-associated properties of transit through the vasculature and invasion of distant tissue sites.

The current view of cancer is evolving beyond the accumulation of genomic and epigenetic aberrations in epithelial cells to one that appreciates the impact of the “soil”² or microenvironment on the formation, propagation and metastasis of tumor cells. Focus of this effort centers on the impact of close contact with cellular members of the stroma and immune system, which generate insoluble extracellular matrix proteins and/or soluble paracrine and autocrine factors. Activated stromal fibroblasts secrete a myriad of soluble factors including SDF-1,³ MMPs,⁴ VEGF-A,⁵ HGF,⁶ Sdc1⁷ and TGF- β ⁸ that have been shown to enhance tumor growth and angiogenesis. As one example, cells of the human breast cell line MCF-7 are weakly tumorigenic in SCID mice, but are strongly tumorigenic when inoculated with stromal fibroblasts.⁹⁻¹⁰ In addition to secreted factors, the impact of cell-cell communication is also coming to the fore as a means by which the microenvironment facilitates oncogenesis. Recent

work by Apostolopoulou et al shows that MCF-7 breast cancer epithelial cells form cadherin-23-dependent, heterotypic adhesions with normal breast fibroblasts when grown in co-culture, and suggests that cadherin-23 upregulation may play a role in the early stages of metastasis.¹¹ A logical extension of cell adhesion or close cell contact is the possibility that tumor cells or their precursors fuse with cells of the local microenvironment. Known examples of cell fusion, along with their demonstrated and potential roles in oncogenesis and metastasis are reviewed here.

II. CONTEXT AND OUTCOMES OF CELL FUSION

A. Spontaneous Heterotypic Fusion Occurs in Nature

Fusion occurs spontaneously between cells of the same type (homotypic) and cells of different types (heterotypic). Homotypic cell fusion was first observed more than eighty years ago in the formation of foreign body giant cells¹² and was soon followed by reports of fusion between trophoblasts of the placenta, myoblasts of muscle fibers and osteoclasts of bone.¹³ However, it was not appreciated until recently that fusion products may form between heterogeneous cell types *in vivo* and that nuclei themselves often fuse to give rise to synkaryons.¹⁴ Spontaneous heterotypic cell fusion *in vivo* was first observed in transplantation studies in animal models and later in humans, both in healthy and diseased states.¹⁵⁻¹⁸ Mesenchymal stem cells and other bone marrow-derived cells (BMDCs) have often been implicated in these studies, especially in synkaryon formation.¹⁹⁻²⁰

B. Cell Fusion Generates Diversity

The immediate consequence of both homotypic and heterotypic cell fusion is tetraploidy, a doubling of the genetic material available to the cell and the first opportunity to augment clonal

diversity. Given the correlation between copy number and gene expression, tetraploidy alone has the potential to radically alter cell state.²¹⁻²² Tetraploidy has also been reported to increase the sensitivity of both yeast and human cells to DNA-damaging agents.²³⁻²⁴ Fusion between cells in different stages of the cell cycle can also result in DNA damage – particularly double-strand breaks mediated by premature chromosome condensation.²⁵⁻²⁶ In addition, tetraploidy has been suggested to “overwhelm” the mitotic machinery, making chromosome missegregation more likely²⁵. A second immediate consequence of cell fusion is an increase in centrosome number. Supernumerary centrosomes can result in multipolar spindles or the missegregation of individual chromosomes after multipolar spindles are focused into bipolar ones.²⁷⁻²⁸ In any scenario, fusion would be expected to increase genetic diversity of the fusion product compared to individual fusion partners.

Of course genetic diversity is likely to result in phenotypic diversity, dependent on the degree of change and the localization of change. Perhaps the most familiar example of how a fusion product attains diversity of phenotype is the hybridoma cell, a Sendai virus-induced fusion of a murine myeloma cell with a B cell from an immunized mouse.²⁹ The entire hybridoma system is based on the assumption that the fusion product has a competitive advantage over the parental cells, as neither parental cell line can survive in selective media. The fusion products of these experiments were known to have highly variable phenotypes. In practice, this made the process of hybridoma selection frustrating, since only a percentage of fusions resulted in nuclear hybrids, a fraction of those produced antibodies, and a small percentage of antibody-producing hybrids were able to be expanded into functional hybridomas.³⁰ The ability of hybridomas to “evolve” upon continuous culture was even used to map genes to specific chromosomes.³¹ In a study that mapped an “IL-6 dependency gene” to human chromosome 21 it was found that newly

fused hybridomas displayed IL-6 dependence, however this dependency was lost at frequencies up to 50% upon continuous culture, suggesting that genetic material was lost after fusion.³¹ Karyotyping of stable clones showed a great variety of seemingly randomized chromosome content. Thus, early hybridomas show a high degree of chromosomal instability (CIN), defined here as an increased and continuous rate of large chromosomal aberrations, including deletions, duplications, or translocations as well as loss or gain of whole chromosomes. Despite the great degree of genetic rearrangement after fusion, hybridoma genotypes eventually stabilize in culture, as evidenced by the extent of their use in industry to provide an extremely pure monoclonal antibody product in a highly reproducible fashion.³²⁻³³

Although the progression from tetraploidy to aneuploidy or diploidy in hybridomas may be dismissed as a product of extreme culture conditions, there is considerable evidence that this process also occurs in normal culture conditions and even *in vivo*. Observations that tetraploid yeast cells could progress to aneuploidy,³⁴ and that cells with more than four centrioles could be found in mouse models,³⁵ along with the fact that multipolar mitoses are often seen in human cancers³⁶ led to the hypothesis that supernumerary centrosomes lead to multipolar cell division in tetraploid cells and diverse aneuploid progeny.³⁶⁻³⁷ However, multipolar spindles are frequently focused into bipolar spindles before anaphase onset and chromosome segregation.²⁸ Ganem et al. recently showed that, even when cells ultimately proceed through a bipolar division, extra centrosomes promote missegregation of individual chromosomes in a variety of human cell lines by merotelic attachment, in which a single kinetochore attaches to microtubules originating from multiple centrosomes.²⁷ If these centrosomes are focused into different spindle poles, this phenomenon can lead to chromosome lagging during anaphase and the production of diverse aneuploid progeny even in the absence of multipolar division.

Diversification of the genome and the phenome could be advantageous in many scenarios beyond the generation of hybridomas. As one example, Grompe and colleagues have reported detailed studies of the consequences of hepatocyte fusion with BMDCs in a regenerative context *in vivo*. It was first shown that hepatocyte-BMDC fusion products had a competitive advantage in the diseased liver microenvironment and were able to completely repopulate the host liver.³⁸⁻³⁹ After diploid fusion products (as determined by a Cre-Lox reporter system) were observed¹⁹ genetic studies were performed to elucidate the mechanism of chromosome loss after cell fusion. Using a three-marker system in which fusion-derived hepatocytes alone expressed β -gal, FAH, and bore a Y-chromosome, ploidy reduction was demonstrated, frequently resulting in aneuploid progeny of diverse karyotypes.⁴⁰ Subsequent single-cell PCR genotyping revealed that parent-specific markers segregated independently via ploidy reduction after cell fusion, with the incidence of loss ranging from 33-70% of cells analyzed. Only 13% of fusion products tested retained all parental markers, suggesting that ploidy reduction is a very common phenomenon after cell fusion *in vivo*. It is also interesting that the incidence of single marker loss did not cluster around 50%, as would be expected for random chromosome loss, again suggesting that environmental pressure may enrich for cells with favorable phenotypes. Later studies also implicated merotelly and chromosome lagging in aneuploidy generation in this process.⁴¹ In addition, it was shown that hepatocytes can regularly increase and reduce their ploidy while maintaining viability and producing high levels of genetic heterogeneity – a process termed the “ploidy conveyor”.⁴¹ It is interesting to note that regrowth of the liver after hepatectomy is associated with an increase in polyploid cells.⁴² Populations of tetraploid fibroblasts have also been observed in a variety of wound healing contexts in humans and mice and the frequency of tetraploidy has been shown to increase during the proliferative phase of wound healing.⁴³

Importantly, these tetraploid cells often appeared in clusters suggesting a clonal evolution, possibly from an initial cell-cell fusion event. It is easy to envision an invading inflammatory BMDC being involved in this context as well. These examples suggest that polyploidy may in fact be an adaptive response to the need to repopulate a damaged tissue.⁴⁴

While genetic recombination is certainly an important event in heterotypic fusion, the mixing of epigenetic factors from diverse cell types may be just as crucial. In a process termed “nuclear reprogramming”,⁴⁵⁻⁴⁶ cell fusion can result in activation or silencing of genes of one parent via outside epigenetic factors. The most well-known example of nuclear reprogramming by the cytoplasm is probably somatic cell nuclear transfer, which has been utilized to reset a mature nucleus to a pluripotent or totipotent state and resulted in the cloning of Dolly the sheep.⁴⁷ Decades ago, it was shown that trans-acting epigenetic factors from one nucleus of a heterokaryon can silence or activate genes in a partner nucleus.⁴⁸⁻⁴⁹ Through work in stem cell biology, it has been shown that fusion of pluripotent murine germ cells with thymocytes from adult mice alters the methylation status of previously imprinted somatic genes.⁵⁰ However, when embryonic stem cells were used as fusion partners instead of germ cells, imprinted genes were not demethylated but hyperacetylation of histones H3 and H4 led to a pluripotent state.⁵¹⁻⁵² The result of these epigenetic changes can be expression of genes already active in one (or both) fusion partners⁴⁸ or expression of genes not expressed in either parent, an outcome seen more recently in the context of cancer.⁵³

An altered phenotype may also be produced solely by the physical changes of a fusion product, specifically an increase in cytoplasmic and/or nuclear volume. Effects of increased volume could include less efficient transfer or decreased concentration of transcription factors and other proteins, less efficient interactions between organelles, and lowered efficiency of

membrane-dependent activities due to an increased ratio of cell volume to organelle surface area.⁴⁴

The process of combining genetic or phenotypic information to create diversity and selective competitive advantages is also an important concept in evolutionary biology. There is considerable evidence of polyploidization in the evolutionary history of many organisms including mammals,⁵⁴ which although not well understood is thought to increase evolutionary innovation through genome recombination.⁵⁵ Furthermore, a recent study on a newly formed (~80 yr) naturally polyploid plant species revealed massive chromosomal instability, with 69% of individuals studied displaying aneuploidy for one or more chromosomes and 76% showing intergenomic translocations.⁵⁶ The high degree of genomic diversity still being generated after ~40 generations of this biennial species suggests that prolonged periods of chromosomal instability may commonly precede genomic stabilization in naturally forming polyploid species. The evolutionary theory of symbiogenesis takes this idea a step further.⁵⁷ It holds that mergers of species, rather than Darwinian evolution via accumulation of mutations, are the drivers of diversity and speciation. The most convincing evidence to support the symbiogenic theory is the finding that mitochondria and chloroplasts are of bacterial origin.⁵⁸ What fraction of evolutionary adaptations can be ascribed to symbiogenesis is unknown, but it is not difficult to imagine a corollary to symbiogenesis, which states that one means by which species or structures of species are merged is via fusion.

III. MECHANISMS OF CELL FUSION

A. Spontaneous Cell Fusion

Cell membranes allow the cell to function independently and preserve self-regulation from outside influence. In normal development, this compartmentalization is overcome by cell-cell fusion only in a tightly regulated manner. The process of fusion is thermodynamically unfavorable owing to the need to expunge water between the cells, the negative and opposing charges of the outer phospholipid bilayer, and the need to disrupt the membrane. One way that the formation of a syncytium is enabled is via specific integral membrane proteins, termed fusogens, which minimize the incredible energy cost required to overcome the merger of the two hydrophobic membranes.⁵⁹ Establishing true fusogens has proven difficult since removal of facilitating proteins from the system reduces overall fusion rates. As technologies advance, many “fusogens” have been contested and shown to be merely adhesion proteins that bring cell membranes in close apposition but do not actually facilitate fusion. Although the mechanisms of spontaneous cell fusion are still not well understood, studies of fusion in normal development have given us some clues.

B. Homotypic Fusion: Macrophages

While some cells, such as myoblasts and placental trophoblasts, are required to fuse for normal development, macrophages are normally present as mononuclear cells in the body, and undergo rare (and inducible) fusion events to form multinucleated osteoclasts and giant cells.⁶⁰ As such, macrophages may prove to be the most useful model to study inducible fusion. When the recent evidence of BMDC fusion with somatic and cancer cells is taken into account, the mechanisms of macrophage fusion become even more interesting.

Osteoclast and giant cell development is thought to progress similarly and include a series of functional steps including induction of a fusion-competent status, chemotaxis, cell-cell

attachment, cytoskeletal rearrangements, and fusion.⁶¹⁻⁶² IL-4 and IL-13 are secreted by a number of immune cells and can induce giant cell formation *in vitro* and *in vivo*,⁶¹ while RANKL and M-CSF can induce osteoclast formation *in vitro*.⁶³ These soluble factors are thought to lead to a fusion competent status by upregulating fusion mediator expression on macrophage cell membranes. For example, IL-4 stimulates DC-STAMP and E-cadherin expression, both of which are implicated in macrophage fusion.⁶⁴⁻⁶⁶ Internal signaling via DAP12 also seems to be important in this process by mediating transcription of other fusion mediators.⁶⁷ Little is known about chemotactic and adhesive factors in macrophage fusion. CCL2 (MCP1) is thought to be important in chemotaxis, as deficiency in mice has been shown to impair giant cell formation while leaving macrophage recruitment unaffected,⁶⁸ and E-cadherin has been implicated in macrophage adhesion.⁶¹ Final temporal regulation of macrophage fusion may be determined by the macrophage fusion receptor (MFR) and its ligand CD47. CD47 is expressed ubiquitously, while MFR is expressed only in myeloid cells and neurons. Additionally, MFR is strongly and transiently expressed in macrophages at the onset of fusion.⁶⁹ Notably, CD47⁷⁰⁻⁷¹ and CCL2⁷²⁻⁷³ are both expressed in diverse cancers⁷⁴ and IL-4 and IL-13 are secreted by CD4⁺ T cells in the breast tumor microenvironment.⁷⁵

It has recently been shown that a podosome-like structure is created around actin foci in fusion-competent myoblasts. These podosomes invade adjacent founder myoblasts and mediate fusion pore formation.⁷⁶ Interestingly, lamellipodia form in IL-4 stimulated macrophages before giant cell formation, and these structures have been suggested to be critical in the fusion process.⁷⁷

C. Heterotypic Fusion: Gametes

Despite its essential role in the generation of life, the most well known example of developmental heterotypic cell fusion is similarly shrouded in mystery. Mammalian reproduction occurs through heterotypic gamete fusion. As a fusion product, the fertilized embryo can proliferate and differentiate into all the tissues of the adult body as well as the extra-embryonic tissues. CD9 is an egg-associated putative fusogen. Knockout mice for CD9 have show severely hampered fertilization⁷⁸ which is restored with polyadenylated CD9 mRNA.⁷⁹ Additionally, CD9 has been shown to generate the strongest observed interactions with the sperm.⁸⁰ In contrast, Izumo is a putative fusogen found only on the sperm membrane following acrosomal reaction.⁸¹ Supporting the role of Izumo as a fusogen is the finding that Izumo-deficient mice have normal sperm migration into the oviduct, motility, zona pellucida penetration, and acrosomal reaction, but are completely infertile.⁸² Furthermore, successful fertilization occurs after artificial injection of Izumo-deficient sperm into oocytes, indicating that Izumo-null mice lacked other developmental defects. Although the expression of each protein is essential for fusion and fertilization, the molecular mechanism of Izumo/CD9 induced fusion is not well understood. For example, it is not known whether other facilitating proteins are required.^{59, 82}

D. Viral-Mediated Fusion

In contrast to spontaneous cell-cell fusion, mechanisms of many virus-cell fusion events have been well characterized.⁸³ The first step of viral fusion is attachment; capsid proteins bind to specific receptor proteins on the cell membrane. Next, depending upon the type of virus, one of two pathways occurs: plasma membrane fusion or endocytosis followed by endosomal membrane fusion. Typically, a hidden fusogenic protein in the envelope is activated either by the

induction of a conformational change upon receptor binding, or exposure to low pH within the endosome. Class I fusion proteins, such as the human immunodeficiency virus type-1 (HIV-1) envelope protein (Env) use a hydrophobic fusion peptide that is only exposed after specific receptor binding or under low pH conditions. The fusion protein then undergoes a conformational change that brings the viral and cell membranes into close apposition to mediate fusion.⁸⁴

After viral infection, cells may express fusogenic proteins such as Env on their cell membranes, facilitating fusion with adjacent healthy cells. This characteristic has been used to induce cell fusion *in vitro* for years⁸⁵ and viruses that are able to fuse cells are nearly ubiquitous in humans.²⁶ This property is especially interesting in the context of oncogenesis in light of recent findings that certain viruses such as HPV are indeed causative of cancer and capable of inducing cell fusion.^{1, 86} It is also worth noting that tumors often create an acidic microenvironment that could activate pH-sensitive viral fusogens.⁸⁷

IV. CELL FUSION AND ONCOGENESIS

CIN and aneuploidy are classic hallmarks of cancer⁸⁸⁻⁸⁹ and are documented consequences of cell fusion.²⁵ However, it is unclear exactly how CIN is initiated in cancer progression. Supernumerary centrosomes, with or without tetraploidy, can lead to CIN due to the formation of merotelic attachments.^{27, 36} It has also been suggested that CIN could arise as a direct result of extra chromosomes through an increased rate of DNA damage^{34, 90} or that increased chromosome content could “overwhelm” the mitotic machinery resulting in missegregation of chromosomes.^{25, 37} As was discussed earlier, cell fusion-induced tetraploidy can lead to aneuploid progeny through a transient period of CIN. Fittingly, the first clue that

fusion may be involved in oncogenesis is that tetraploidy is common in premalignant lesions and often gives way to aneuploidy in later stages.^{25, 91-92} The best studied example of this phenomenon is probably Barrett's esophagus, a premalignant condition in which tetraploid cells are predictive of progression into both aneuploidy and cancer.⁹³⁻⁹⁴ Tetraploidy has also been detected in premalignant lesions in cervical cancer,⁹⁵ head and neck squamous cell carcinoma,⁹⁶ and Kaposi sarcoma,⁹⁷ however it is unknown whether tetraploid cells in these lesions progress to malignancy. Direct evidence for carcinogenesis as a result of tetraploidy comes from a 2005 study in which p53^{-/-} tetraploid cells were derived through chemically inhibiting cytokinesis.⁹⁸ These p53^{-/-} tetraploid cells formed tumors when implanted subcutaneously in nude mice while isogenic p53^{-/-} diploid cells did not. Karyotyping of resultant tumors showed they were near-tetraploid with numerous structural rearrangements. The observations that a majority of cancer cell lines in the NCI-60 drug screening panel⁹⁹ and elsewhere¹⁰⁰⁻¹⁰² are hyperdiploid and that karyotypes are generally preserved between cell lines and the primary tumors they were derived from^{100, 103} suggest that the progression from tetraploidy to aneuploidy may be common in many cancers *in vivo*.

It has been reported that there exists a p53-dependent "tetraploidy checkpoint" that must be overcome for proliferation of these cells.¹⁰⁴⁻¹⁰⁵ However, subsequent experiments using the same cell type have failed to replicate this finding.^{24, 106} Even though cell cycle arrest is not directly related to DNA content, suppression of proliferation is common in fusion products, as evidenced by the low survival of hybridomas³⁰ and lack of proliferation of developmental fusion products such as osteoclasts and muscle fibers.¹³ Additional proof was provided by Duelli et al. in the context of viral-induced cell fusion. It was observed that cell fusion induced by viral infection of normal human fibroblasts, but not the viral infection itself, caused cell cycle

arrest.¹⁰⁷ However, if one parental cell expressed the adenoviral oncogene E1A or a mutated form of the tumor suppressor p53 the fusion products proliferated, producing diverse aneuploid progeny, some of which were capable of producing tumors in nude mice.¹⁰⁸ Furthermore, Duelli et al. have suggested that fusion-specific mechanisms of combining DNA content from cells in different epigenetic states, possibly including premature chromosome condensation, may result in instability, double strand breaks, and consequent translocations often seen in aneuploid progeny.²⁶

An alternative explanation of the appearance of diverse aneuploid progeny after a period of CIN in cancer progression is progression through “telomere crisis”. This theory holds that while a great majority of cells will trigger senescence or apoptosis pathways upon sufficient erosion of telomeres (i.e. reaching the Hayflick limit), oncogene expression may allow continued proliferation to the point of crisis. Telomere crisis is characterized by genetic aberrations including chromosomal end-to-end fusions, translocations, losses, and duplications. Out of this period of genetic instability, rare cells emerge that are able to maintain telomere length by reactivating telomerase. These dysregulated aneuploid cells may then go on to form malignant tumors.¹⁰⁹⁻¹¹⁰

In a landmark study of *in situ* genome instability in breast cancer, Chin et al. demonstrated a transient period of genomic instability coinciding with telomerase activation and with transition from ductal hyperplasia to ductal carcinoma *in situ*.¹¹⁰ This period of instability was attributed to telomere crisis, although telomere length was also shown to decrease at a steady rate throughout disease progression. However, two observations made by Chin and colleagues are reminiscent of CIN following cell fusion. First, it was noted that the increase in genome instability was contemporaneous to an increase in DNA content. Second, the frequency of

anaphase bridges were low in hyperplasia, highest during the period of instability, and reduced thereafter. The occurrence of anaphase bridges is often used as an indicator of telomere crisis,¹¹¹⁻¹¹² but can also occur as a consequence of chromosome lagging due to supernumerary centrosomes and merotelically as discussed earlier.^{27, 113} Thus, the same temporal pattern of anaphase bridge frequency peaking alongside increased DNA content and genomic instability would be expected to occur after cell fusion.

Further confusing the debate around CIN and aneuploidy in the context of cancer is that aneuploidy can act as a tumor promoter or suppressor depending on the cellular context.¹¹⁴ Aneuploidy caused by depletion of the mitotic checkpoint component BubR1 promotes tumor formation in the colon of APC^{Min/+} mice, which are predisposed to intestinal tumors due to heterozygous expression of a truncation mutant of the Adenomatous Polyposis Coli tumor suppressor, but inhibits tumor formation in the small intestine.¹¹⁵ Similarly, monosomy of 33 genes on mouse chromosome 16 enhances intestinal tumor formation in APC^{Min/+} mice, but trisomy of these same 33 genes suppresses tumor formation.¹¹⁶ Aneuploidy caused by partial reduction of the mitotic checkpoint component Bub1 drives liver tumor formation, but further reducing the level of Bub1 causes an increased rate of chromosome missegregation and suppresses liver tumors.¹¹⁷ Both loss and overexpression of securin, a protein that prevents premature sister chromatid separation, result in aneuploidy.¹¹⁸⁻¹¹⁹ However, loss of securin reduces pituitary tumor formation in Rb^{+/-} animals,¹²⁰ while overexpression of securin facilitates pituitary tumor development.¹²¹ Finally, epidemiological studies have shown that Down's syndrome/trisomy 21 patients have much higher rates of hematopoietic malignancies, but lower incidence of solid tumors.¹²²⁻¹²⁴

In another study, Weaver et al. utilized a low-expression Centromere-associated Protein-E (CENP-E^{+/-}) model to induce aneuploidy and CIN due to whole chromosome gain and loss *in vitro* and *in vivo*.¹¹⁴ When CENP-E^{+/-} transgenic mice were inspected for spontaneous tumor formation, it was found that transgenic animals developed higher rates of lymphomas and lung tumors than their littermates, but significantly decreased rates of tumorigenesis in tissues normally prone to tumor formation, such as the liver. Additionally, CENP-E^{+/-} animals exhibited decreased tumorigenesis compared to wild type animals when exposed to the well characterized carcinogen DMBA and a highly significant increase in tumor-free survival in the absence of the ARF tumor suppressor when compared to ARF^{-/-}, CENP-E^{+/+} littermates. Another important observation of the study was that aneuploidy in nontransformed cells *in vivo* was characterized by a disproportionate tendency toward whole-chromosomal loss relative to gain.

Taken together, these results argue that aneuploidy promotes tumorigenesis in otherwise genetically stable tissues and cells but inhibits tumor formation in tissues with a preexisting rate of CIN. This mechanism may explain why cell fusion is tumor suppressive in certain contexts,^{74, 125-126} which led to the early belief that tumor cell fusion always suppressed malignancy and even aided in the discovery of tumor suppressor genes.¹²⁷

If high or sustained levels of CIN could result in the extinction of a neoplasia, Storchova et al. raise the possibility that cell fusion via the introduction of additional genetic material gives a sort of “cushion” to the deleterious effects of CIN, as redundant genes could compensate for the loss of single alleles or whole chromosomes.⁸⁸ It is also possible that a polyploid genotype after fusion has a larger selection of dormant genes that can be activated in response to environmental challenge and thus display the remarkable adaptive ability found in tumor cells.^{48,}

⁵¹ In any case, in order for a clinically significant tumor to arise, at least one stable genome

capable of continuous proliferation must be generated from the period of CIN (Figure 1A). This seems to be the case in many cancers by the time of clinical appearance,^{44, 60, 128} and is further supported by the observation that karyotypes from relapsed tumors many years after treatment can be identical to the original tumor.¹²⁹⁻¹³⁰

V. CELL FUSION AND METASTASIS

Although much progress has been made in recent years in understanding the pathways of metastasis and the role of the microenvironment in this process,¹³¹ very little is known about the generation of metastatic cells within a previously non-metastatic primary tumor. The question of why only a tiny fraction of transformed cells are able to free themselves from the cell and ECM adhesions of the tumor site, migrate through the surrounding tissues and basement membranes, intravasate into the bloodstream or lymphatic system, and extravasate, invade, and proliferate at a distant site is a critical one for the development of effective therapeutics. The importance of understanding this process is underscored by the fact that a majority of cancer deaths are attributed not to primary tumors, but to complications arising from distal metastases. A recent publication¹³² further emphasizes the importance of understanding metastasis by pointing out that of the six famed “hallmarks of cancer”,¹³³ only one – tissue invasion and metastasis – can be used to distinguish a life-threatening malignant tumor from an essentially harmless benign tumor.

The dogmatic view of metastasis is that it evolves gradually during tumor evolution, as part of the selective adaptation of the tumor genome.¹³⁴ In this linear progression model, primary tumor cells accumulate genetic changes randomly, those mutations that support survival and proliferation in the tumor microenvironment are selected for, and clonal expansion occurs

within the tumor. Eventually, a cell arises with a combination of chance genetic alterations that enable it to depart the primary tumor and take up residence elsewhere in the body. This model has become popular for good reason. First, it follows logically from the discovery of oncogenes in malignant transformation and second, it does an excellent job of explaining the positive clinical correlation between tumor size and frequency of metastasis.¹³⁴⁻¹³⁵ A large tumor has presumably been in existence longer than a smaller tumor, giving it both more time for accumulation of mutations and a larger cell population in which to select for cells capable of metastasis. However, several lines of evidence argue against the linear progression model of metastasis.

First, advances in parallel-sequencing technology now allow for whole-genome analysis of primary and metastatic tumor cells. One recent study compared the whole genome of a brain metastasis to that of the primary breast tumor and found only two *de novo* mutations in the metastatic tumor.¹³⁶ One was a silent mutation while the other was determined to be non-essential to metastasis, suggesting that a mechanism other than genetic mutation initiated the metastatic process. It is important to note that this methodology would not detect polyploidy of the tumor cells.

Another argument involves the growth kinetics of primary and metastatic tumors. The linear progression hypothesis predicts that significant time and cell divisions will be required for a tumor cell to gain and “fix” the chance mutations needed for metastasis. Therefore, according to this hypothesis primary tumors should be of sufficient size to sustain the establishment of clonogens that form with low frequency. In fact, metastases are often seen in early disease stages, and 5-10% of patients diagnosed with cancer in Europe and the United States present with unknown primary tumors.¹³⁷⁻¹³⁸ For the linear progression hypothesis to hold in these cases,

growth rates of metastases would need to be far greater than those of the primary tumor. Primary and metastatic breast cancer growth rates have been well studied¹³⁹⁻¹⁴⁰ and argue against this possibility. Several methods of investigation have shown that growth rates of primary and metastatic tumors are comparable at the time of diagnosis, typically within a factor of two.¹³⁴

A third, primarily hypothetical argument against linear progression has been put forward by George Parris¹⁴¹ and expands on the discussion of CIN and consequent genomic stabilization above. If a tumor is conceptualized as a new, “parasitic” species within the host,¹⁴² it will be subject to the ecological pressures of any other species. By the widely known ecological concept of Muller’s Ratchet,¹⁴³ an asexual population with only genetic mutations available to generate diversity may gain a momentary genetic advantage via a desirable mutation. However, when a deleterious mutation occurs in this asexual population it must (with the exception of back mutations) be passed on to all progeny. As a given mutation is more likely to be deleterious than advantageous, undesirable mutations build up in an asexual population until it finally becomes extinct. In the context of cancer progression, this theory would allow for the formation of neoplasia due to somatic mutations, but tumors would be expected to become extinct before clinical relevance or metastasis. We and others^{13, 74, 141} argue that a “sexual” method of reproduction – such as cell fusion – that allows for genetic recombination offers a more likely explanation for tumor progression into metastasis than the linear progression model (Figure 1B). This hypothesis is initially supported by the correlation between the most immediate consequence of genetic recombination – aneuploidy – and poor prognosis in a variety of cancers^{92, 144-147} as well as the finding that polyploidy is strongly correlated with growth rate in many species¹⁴⁸. In more concentrated studies, it was found that polyploidy in the liver was increased in faster growing mouse pups¹⁴⁹ and in rat hepatocytes after growth hormone

stimulation.¹⁵⁰ Thus, fusion-induced polyploidy may be an adaptive response to the increased rate of proliferation throughout disease progression.

A. Tumor cell fusion with other tumor cells

If fusion is a viable means by which metastasis is initiated, the next question is “which two (or more) cells fuse?” The definitive answer to this question remains elusive, but several studies are suggestive of certain pairings. One pairing is fusion between tumor cells. If tumor cells fuse with each other, detection of such an event within a single tumor is challenging, as most detection techniques rely on overlapping lineage-specific markers to identify fusion partners. Accordingly, a fusion event between phenotypically identical tumor cells would be undetectable in most experimental systems. However, spontaneous fusion between cancer cells has been observed *in vitro*. As early as 1984, it was observed that multi-nucleated giant cells arose in suspension cultures of B16 melanoma cells.¹⁵¹ More recently, co-culture of two variants of the MDA-MB-231 breast cancer line, one of which metastasizes almost exclusively to bone and the other primarily to the lung, resulted in fusion hybrids that had gene expression signatures of both parental strains and retained strong metastatic ability to both lung and bone *in vivo*.¹⁵² Interestingly, fusion products were phenotypically and genomically stable at a nearly doubled genome size after passage *in vivo* up to the time of publication (almost 1 year).

B. Tumor cell fusion with local non-malignant cells

Evidence of fusion between xeno- or allogeneic transplanted malignant cells and host cells *in vivo* was reported repeatedly in the 1970s and early 1980s,¹⁵³⁻¹⁵⁴ often resulting in increased metastatic ability. However, it was not until recently that advances in genetic profiling

techniques such as fluorescence *in situ* hybridization (FISH) could provide conclusive evidence of synkaryon formation.

In the last decade, fusion of epithelial tumor cells with local endothelial and other stromal cells *in vivo* has been reported. In one study, human breast cancer cells were injected into the tail vein of nude mice. Subsequent analysis of lung sections revealed that 0.5-2.0% of tumor cell nuclei contained both human and murine DNA.¹⁵⁵ A portion of these hybrid cells also stained positively for the endothelial marker von Willebrand factor, suggesting that at least some of the murine fusion partners were of endothelial origin. FISH analysis of the hybrid cells revealed consistent spatial separation of human and murine DNA into distinct subcompartments of hybrid nuclei, a phenotype that was reproduced *in vitro*. Although the relevance of this spatial separation is unknown, it is interesting to speculate on the epigenetic and mitotic consequences of this arrangement. It is possible that chromosomes of one fusion partner are epigenetically favored over the other, resulting in transcriptional profiles very similar to parent cells. Alternatively, this compartmentalization could allow for lineage-specific DNA content to be easily separated in subsequent asymmetric cell divisions,³⁷ resulting in progeny with little or no genomic alterations. Because of the great similarities between the progeny of fusion products and unfused cells either of these mechanisms could lead to underestimation of the frequency of cell fusion by common detection techniques

Further evidence for tumor cell-stromal cell fusion comes from implantation of primary human breast cancer cells from a pleural effusion into the mammary glands of nude mice.¹⁵⁶ Resultant tumor nuclei stained positive for both human and murine DNA. In addition, a cell line was created from the tumor that had a spindle-shaped stromal morphology and stained positive for several stromal markers. After immortalization, FISH analysis indicated that ~64% of

interphase nuclei were mouse-human hybrids, while a significant portion of mitotic cells showed mouse/human chromosomal translocations. The DNA content of the analyzed synkaryons was ~4N in early passages, but gradual reduction of chromosomes was observed upon serial passaging. These data suggest that increased chromosomal content was beneficial for tumor cells adapting to a new environment *in vitro*. Gradual loss of chromosomes with passage number could represent the stabilization of a new karyotype after cell fusion-induced CIN or simply the reduction of genetic load of cultured cells by loss of DNA content unnecessary for survival. Similar behavior is often observed in antibiotic resistant bacterial and mammalian cell lines upon removal of the selective pressure of antibiotics in the culture media.¹⁵⁷

A more recent study investigated long-term gene expression of hybrid cells formed after transplantation of a primary human glioblastoma into a hamster cheek pouch.¹⁵⁸ After a year of passage *in vivo*, metastases were found to contain primarily hamster DNA, but still retained genes from at least six different human chromosomes as detected by PCR. Additionally, histochemical examination showed protein expression of at least three human genes after one year of passage. All three of the human proteins detected (CD74, CXCR4, and PLAGL2) have been implicated in cancer progression,¹⁵⁸ again suggesting selective retention and/or expression of genes beneficial for tumor cell survival and proliferation after cell fusion.

C. Tumor cell fusion with BMDCs

Perhaps the longest¹⁵⁹ and most extensively investigated tumor cell fusion partners have been bone-marrow derived cells, especially immune cells such as macrophages. This is in part because the consequences of tumor cell fusion with immune cells agree well with numerous observations of cancer progression.

Tumors have been described as “wounds that do not heal”¹⁶⁰ and as such, recruit immune cells through the activation of the body’s natural inflammation response. A plethora of BMDCs are known to be present in the tumor microenvironment (reviewed in¹⁶¹) and many, including CD4⁺ T cells¹⁶², mast cells¹⁶³, B cells¹⁶⁴, and macrophages¹⁶⁵ have been implicated in cancer progression or poor prognosis. Interestingly, chronic inflammation or other tissue injury has been shown to induce BMDC fusion in a wide variety of tissues, both in a cancer context^{53, 166} and in normal regenerative processes^{38-39, 167-168}. Especially interesting is the observation that BMDC fusion with diseased hepatocytes results in fusion products that repopulate the liver due to a selective advantage in the microenvironment¹⁹ – a model that could be recapitulated in the tumor microenvironment.

Given these observations, it is not surprising that all three clinical case studies implicating cancer cell fusion have suggested BMDCs as the fusion partner. In two studies reported by Pawelek and colleagues, patients with a prior bone marrow transplant developed renal cell carcinomas.^{20, 169} In both cases, marrow-donor DNA was detected in mononuclear tumor cells. In the most striking example, the donor Y-chromosome was identified via FISH analysis in mononuclear tumor nuclei also containing three copies of the female host’s 17th chromosome, a signature of the tumor. Importantly, the Y chromosome was detected in a small area at the border of the tumor accounting for ~10% of the tumor area. This observation suggests a possible clonal expansion from the initial fusion event. In a third case, FISH analysis indicated that up to 48% of nuclei in multinucleated osteoclasts of a multiple myeloma patient were of myeloma origin, with all nuclei maintaining activation of transcription.¹⁷⁰

It has also been suggested that carcinoma cells can undergo an epithelial-to-mesenchymal conversion during the transition from benign to malignant tumors. During this transition, cells

lose tight cell-cell contacts and E-cadherin expression, and gain migratory and invasive capacities of mesenchymal cells (reviewed in ¹⁷¹). This change in phenotype can be easily imagined as a result of fusion of a tumor cell with an immune cell that depends on efficient migration to function effectively. Indeed, melanoma cell/macrophage fusion products have shown increased migratory capacity *in vitro*¹⁷² and greater metastatic potential *in vivo*¹⁷³ compared to the parent melanoma line.

Macrophages are an especially promising fusion partner candidate, as they routinely fuse *in vivo* to form osteoclasts and giant cells.⁶⁹ It is worth noting that macrophages also share many characteristic properties of tumors, such as angiogenesis, protease secretion, and growth factor and other cytokine production.¹⁷⁴ Pollard and colleagues have pioneered the study of tumor-associated macrophages (TAMs) in mice models and have suggested that TAMs are essential for metastasis.¹⁷⁵ In human patients, macrophage density around the primary tumor has been correlated to poor prognosis in several studies.^{165, 176-177}

The characteristics of macrophage/melanoma fusion products *in vitro* have been studied extensively by Pawelek and colleagues and have been shown to exhibit multiple metastatic characteristics absent in the parent melanoma line, including increased motility,¹⁷² increased proto-oncogene expression,¹⁷⁸ and macrophage-associated expression of β 1,6 oligosaccharides.¹⁷⁹ Notably, many of these characteristics were reproduced after culturing cells from spontaneous metastases developed *in vivo*.¹⁷³ In this important study, a nude mouse with a homozygous tyrosinase mutation (c/c) developed a tumor after subcutaneous implantation of wild type (C/C) melanoma cells. Genetic analysis of metastases revealed a C/c genotype and a 30-40% increase in DNA content, suggesting the tumor cells had fused with host cells, possibly with metastasis as a direct consequence. Subsequent *in vitro* culture of cells isolated from the

metastases revealed characteristics similar to artificially derived melanoma-macrophage hybrids, such as increased motility and β 1,6 oligosaccharide expression.

Additional evidence of *in vivo* tumor cell fusion with macrophages has been supplied recently in a study by Powell et al., in which green fluorescent protein (GFP)-labeled macrophages were introduced via parabiosis into a host harboring β -galactosidase-expressing intestinal tumors.⁵³ Double-labeled cells were observed in up to 20% of the tumor epithelia after parabiosis, however, as the intestinal epithelium completely renews every 3-5 days¹⁸⁰ it is unclear whether labeled macrophages fused with tumor epithelia or rather with a progenitor cell that later differentiated into epithelium, as has been shown previously.¹⁶⁶ In any case, transcriptome analysis of fusion products revealed transcription profiles with similarities to both native epithelial and macrophage transcriptomes. Significantly, over 3% of differentially regulated transcripts in the fusion products were unique in the fusion product compared to either parental cell line, providing evidence that nuclear reprogramming following cell fusion can result in gene expression completely distinct from either parent cell.

VI. ALTERNATIVE MECHANISMS OF GENE TRANSFER

Although cell fusion offers a promising route for genetic recombination and diversity generation within tumors, it is not the only possible mechanism. Macrophages also routinely perform phagocytosis and digestion of apoptotic cells, a process that has been shown to result in horizontal transfer of oncogenes into the phagocytic host.¹⁸¹⁻¹⁸² Macrophages are known to associate extensively with necrotic areas in advanced tumors¹⁷⁷ and it is reasonable to speculate that clearance of necrotic debris by macrophages may also result in genetic transfer of tumor cell DNA into the macrophage genome.

Tumor cell secretion of microvesicles via membrane blebbing and other mechanisms has been a recent focus of study.¹⁸³ These microvesicles have not been shown to contain DNA, but commonly harbor RNA and proteins, including activated oncogenic proteins.¹⁸⁴ Microvesicles could therefore transfer information between tumor cells or from tumor cells to the stroma through RNA or protein, bypassing the need for genetic recombination. Similarly, membrane nanotubes allow for transfer of vesicles and signaling molecules between cells, although evidence of these structures *in vivo* is lacking.¹⁸⁵

It is also possible that information flows in the opposite direction, from the stroma to the tumor. A recent model of tumor progression returns to the idea of the tumor as a parasite. The model posits that tumor cells induce autophagy in the stromal microenvironment through oxidative stress, resulting in a release of nutrients that are used by the tumor for continued growth.¹⁸⁶ Although autophagy is normally thought to preserve genomic DNA content, mitochondrial DNA could be transferred to the tumor in this manner. Alternatively, information could again be transferred via RNA or proteins.

Finally, naked DNA is known to be taken up and expressed by a variety of cell types *in vivo*.¹⁸⁷ It is possible that DNA is released into the tumor microenvironment through apoptosis or necrosis and is simply randomly incorporated into the genome of tumor or stromal cells.

VII. DETECTION OF CELL FUSION

Given the potential impact, it is surprising that fundamental aspects of tumor cell fusion are unknown, including the soluble or insoluble signals that trigger fusion, the cell surface proteins responsible for mediating fusion, the kinetics of fusion within the metastatic cascade, or the mechanism of reprogramming and the functional capacity of hybrid cells after fusion.

Hindering discovery in this area is lack of appropriate technology to 1) identify fusion partners

poised to fuse and to 2) track fusion products over time. To address this problem we have recently developed imaging and characterization technologies to accurately identify fusion products immediately after cell fusion and to track fusion products over time both *in vitro* and *in vivo*.

A. Historical Methods

The origin of a cell as the product of a fusion event can be difficult to deduce since in many cases hybrid cells are morphologically identical to unfused cells (Figure 2B). Three methods have been used traditionally to overcome this difficulty. First, cell fusion can be detected using fluorescent cytoplasmic dyes which diffuse freely through the membranes of live cells. Once inside the cell, these mildly thiol-reactive probes react with intracellular components to produce cells that are fluorescent for at least 24 hours after labeling. Different dyes are used to label each fusion partner and fusion products are discerned by detecting overlapping fluorescence emission via flow cytometry or fluorescence microscopy. This method is ideal for short term *in vitro* studies; however *in vivo* studies are not possible and the fluorescence signal is undetectable at 72 hours in proliferating cells. In addition, dead cells can be endocytosed and the cell dye transferred as a consequence leading to false positives. Second, cell fusion can be detected by the complementary action of genes; most commonly, the Cre-Lox system.¹⁸ This method is robust, detecting only true fusion events and can be used *in vivo*. However, available reporter systems (i.e., beta-galactosidase, fluorescent proteins) limit *in vivo* analysis to excised tissues precluding the tracking of fusion events in the same organism over time. Third, fusion events can be detected by probing the DNA of different species or genders (X, Y chromosomes). When a cell of one species/gender fuses with a cell of another species/gender, *in situ* hybridization probes can be generated to species/gender-specific sites in the genome. More

recently, genetic techniques such as single nucleotide polymorphism (SNP) and short-tandem repeat (STR) analysis have been utilized to identify DNA from multiple parents in fusion products.¹⁸⁸ However, these methods of detection of fusion events are also limited to excised tissue. Thus, there is a distinct lack of means to detect and track fusion products long term *in vitro* and *in vivo*.

B. New Approaches

We have developed two new approaches for the detection of fusion products. The first utilizes bimolecular fluorescence complementation (BiFC). BiFC is a method of viewing the association of proteins inside living cells. Intact GFP (and its variants YFP, BFP, RFP, etc.) is fluorescent, and this property can be reconstituted when these proteins are broken into two halves by making each into an interactive fusion protein (Figure 2A).¹⁸⁹⁻¹⁹¹ Fluorescence is detected and recorded via traditional, time lapse, fluorescence microscopy. We believe this technique to be a powerful tool for detecting fusion *in vitro* and will be especially useful to determine the mechanism by which the fate of tumor cell hybrids is accomplished (i.e., nuclear fusion, rearrangement of genetic material or other). Due to the inducible nature of the signal (i.e., fluorescent signal is detected only after a fusion event, instead of detection of overlapping fluorescent signals), the incidence of false-positives is essentially zero. In addition, the hybrids synthesize accumulating amounts of BiFC genes over time and so signal intensity increases over time (Figure 2B), instead of degrading over time as is the case for cytoplasmic dyes. However, this approach is limited in that it cannot easily be adapted to *in vivo* systems.

To detect fusion products *in vivo* we have developed an approach to trigger bioluminescence upon fusion. We have developed a construct encoding the firefly (*Photinus*

pyralis) luciferase gene placed downstream of a stop codon flanked by LoxP sequences (Figure 3A). When cells expressing this gene fuse with cells expressing the Cre protein, the LoxP sites are recombined resulting in excision of the stop signal and expression of luciferase (Figure 3B).¹⁹² Akin to the BiFC method, this is an inducible method thereby limiting the incidence of false-positive signals. Unlike existing methods which utilize the Cre/Lox system, we have incorporated a “living” detection signal and thereby afford for the first time the opportunity to track the kinetics of cell fusion *in vivo*.

VIII. CANCER RELEVANCE

Despite mounting evidence that cell fusion or transfer of genetic material by various mechanisms could contribute to carcinogenesis and metastasis, critics contend that spontaneous fusion occurs too rarely to contribute in a relevant way to the initiation and propagation of diseases like cancer. In response, we offer a few points for consideration. First, we point to the lack of technology sensitive enough to determine the relative frequency of spontaneous fusion between tumor cells or their precursors with surrounding cell types. As noted above, the task is complicated by the uncertainty of rearrangement of cytoplasmic and nuclear components and the relative speed with which rearrangement takes place.

The choice of model system will be important to the assessment of the role of fusion in the future. Since it is unlikely that fusion assays will ever be done in humans, rodent models are an obvious choice. However, many mouse models are not spontaneously metastatic. The human tumor cell lines or human grafts that are in common use have already progressed past the point of genetic evolution likely to be catalyzed by cell fusion, and results from these may not reveal the full potential of this mechanism. Even if early stage lesions were transplanted, the mouse

hosts will be immune-compromised, and this microenvironment may therefore be deficient in key cell fusion partners. It will be important to choose the correct assay to test this hypothesis.

IX. CONCLUSION

We have discussed the processes that regulate cell fusion, as it occurs naturally and spontaneously to govern normal tissue development and functionality, and the evidence for novel cell fusion events (and/or genetic transfer) that occur during pathogenic processes. These include viral infections, which include fusion events at various points of their life cycles, and the immune reactions that characterize inflammation. The details of these processes are known, including their molecular mediators. Given the emerging importance of inflammatory mediators during metastasis, it seems a logical extension to propose that cell fusion will be associated with this process, and that it could indeed be a functional effector of neoplastic changes. Cell fusion offers an opportunity for rapid genomic evolution. It may offer practical solutions to explain the (arguably) paradoxical timelines for tumors, and to generate mechanisms for the evolution of the massively rearranged genomes that are so characteristic of these tumors. Cell fusion can account for re-assortment of combinations of mutant and normal genomes in various copy numbers. It also offers the potential to acquire cytoplasmic determinants of function (including mitochondria, trafficking components and cell signaling-related functions) that have been shown historically to be powerful mediators of the cancer cell phenotype. These functionalities may be acquired only transiently, to enable for example the enhanced motility or altered metabolism required for metastasis, and may largely revert after the fusion products resolve to stable daughter cells in metastatic outgrowths. The potential of this novel hypothesis stands on the brink of a full evaluation, with the development of new tools and methods. If these studies generate evidence

in support of this hypothesis, this avenue opens the way to a whole new class of therapeutics that are likely to be highly selective for pathogenic processes.




Figure 1. Schematic of cancer progression via cell fusion. **A)** Fusion can lead to oncogenesis. An initial fusion event leads to an intermediate tetraploid fusion product with doubled centrosome content. This intermediate is unstable and is capable of progression into malignancy through several mechanisms. **B)** Fusion can lead to metastasis. Cell fusion or alternative methods of genetic transfer impart new phenotypic capabilities to the tumor cell which enable the cell to metastasize.




Figure 2. Detection of cell fusion *in vitro* via BiFC. **A)** Schematic of BiFC mechanism. Each BiFC construct contains half a YFP gene fused to genes encoding histone H3.1, which naturally dimerizes in the cell. The two BiFC constructs are transduced into separate cells. When the cells fuse, the YFP protein is reconstituted and a fluorescent signal is generated. **B)** Morphologic comparison of fusion products with unfused cells.¹⁹¹ Plasmids corresponding to complementary BiFC constructs (YN-CBX5 and YC-CBX5) were transfected into separate populations of COS-1 cells. After transfection, populations were mixed and fusion was induced with poly(ethylene glycol). Fusion signals (green) were detected using fluorescence microscopy. The morphology of fused cells was monitored via time-lapse imaging for 30 hours. The initial fusion product is a clearly larger cell (black arrow, first two frames). When this cell divides, the four daughters remain green (and would be difficult to distinguish from other non-fused cells (white asterisk) were it not for the BiFC label).




Figure 3. Detection of cell fusion *in vivo* via Cre-LoxP bioluminescence. **A)** Schematic of Cre-LoxP bioluminescence mechanism. Upon donor/recipient cell fusion, the Cre protein excises the floxed stop codon and luciferase is expressed in the fusion product. **B)** Detection of cell fusion *in vivo* via bioluminescent imaging. Human MSCs were transfected with two plasmids, one containing luciferase downstream of a floxed stop codon and the other containing the viral fusogen VSVG. Transfected MSCs were then transplanted into Cre-expressing mice. Luminescent signal was present in experimental mice (top, right mouse) but not in sham controls (top, left mouse). Excision of organs (bottom) revealed luminescent signal, indicative of fusion, in multiple tissues including the heart (arrow). **C)** FISH analysis of bioluminescent heart tissue.¹⁹³ Insets display fusion products with nuclei staining positive for both human centromeres (red) and mouse centromeres (green). One fusion product (bottom right) is undergoing mitosis. Scale bar = 25µm.

References

1. Gao P, Zheng J. High-risk HPV E5-induced cell fusion: a critical initiating event in the early stage of HPV-associated cervical cancer. *Journal of virology*. 2010;7:238.
2. Paget S. The distribution of secondary growth in cancer of breast. *Lancet*. 1889;1:571-3.
3. Huang M, Li Y, Zhang H, Nan F. Research Breast cancer stromal fibroblasts promote the generation of CD44+CD24-cells through SDF-1/CXCR4 interaction. 2010.
4. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. *Cell*. 2010;141(1):52-67.
5. Pinto MP, Badtke MM, Dudevair ML, Harrell JC, Jacobsen BM, Horwitz KB. Vascular Endothelial Growth Factor Secreted by Activated Stroma Enhances Angiogenesis and Hormone-Independent Growth of Estrogen Receptor-Positive Breast Cancer. *Cancer research*. 2010;70(7):2655.
6. Tyan SW, Kuo WH, Huang CK, Pan CC, Shew JY, Chang KJ, Eva YHPL, Lee WH. Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. *PloS one*. 2011;6(1):e15313.
7. Su G, Blaine SA, Qiao D, Friedl A. Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. *Journal of Biological Chemistry*. 2007;282(20):14906-15.
8. Wu M, Jung L, Cooper AB, Fleet C, Chen L, Breault L, Clark K, Cai Z, Vincent S, Bottega S. Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice. *Proceedings of the National Academy of Sciences*. 2009;106(17):7022.
9. Trimis G, Chatzistamou I, Politi K, Kiaris H, Papavassiliou AG. Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors. *Human molecular genetics*. 2008;17(22):3596-600.
10. Kiaris H, Chatzistamou I, Trimis G, Frangou-Plemmenou M, Pafiti-Kondi A, Kalofoutis A. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. *Cancer research*. 2005;65(5):1627.
11. Apostolopoulou M, Ligon L. Cadherin-23 Mediates Heterotypic Cell-Cell Adhesion between Breast Cancer Epithelial Cells and Fibroblasts. *PloS one*. 2012;7(3):e33289.
12. Forkner CE. THE ORIGIN AND FATE OF TWO TYPES OF MULTI-NUCLEATED GIANT CELLS IN THE CIRCULATING BLOOD. *The Journal of experimental medicine*. 1930;52(2):279.
13. Duelli D, Lazebnik Y. Cell fusion: a hidden enemy? *Cancer cell*. 2003 May;3(5):445-8.
14. Ogle BM, Cascalho M, Platt JL. Biological implications of cell fusion. *Nature reviews Molecular cell biology*. 2005 Jul;6(7):567-75.
15. Gussoni E, Bennett RR, Muskiewicz KR, Meyerrose T, Nolta JA, Gilgoff I, Stein J, Chan Y, Lidov HG, Bonnemann CG. Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation. *Journal of Clinical Investigation*. 2002;110(6):807-14.
16. Gibson AJ, Karasinski J, Relvas J, Moss J, Sherratt TG, Strong PN, Watt DJ. Dermal fibroblasts convert to a myogenic lineage in mdx mouse muscle. *Journal of cell science*. 1995 Jan;108 (Pt 1):207-14.
17. Weimann JM, Johansson CB, Trejo A, Blau HM. Stable reprogrammed heterokaryons form spontaneously in Purkinje neurons after bone marrow transplant. *Nature cell biology*. 2003 Nov;5(11):959-66.
18. Alvarez-Dolado M, Pardal R, Garcia-Verdugo JM, Fike JR, Lee HO, Pfeffer K, Lois C, Morrison SJ, Alvarez-Buylla A. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. *Nature*. 2003 Oct 30;425(6961):968-73.
19. Wang X, Willenbring H, Akkari Y, Torimaru Y, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, Olson S, Grompe M. Cell fusion is the principal source of bone-marrow-derived hepatocytes. *Nature*. 2003 Apr 24;422(6934):897-901.

20. Yilmaz Y, Lazova R, Qumsiyeh M, Cooper D, Pawelek J. Donor Y chromosome in renal carcinoma cells of a female BMT recipient: visualization of putative BMT-tumor hybrids by FISH. Bone marrow transplantation. 2005 May;35(10):1021-4.
21. Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozenblum E, Ringnér M, Sauter G, Monni O, Elkahoun A. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer research. 2002;62(21):6240.
22. Pollack JR, Sørli T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Børresen-Dale AL, Brown PO. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proceedings of the National Academy of Sciences. 2002;99(20):12963.
23. Hau PM, Siu WY, Wong N, Lai PB, Poon RY. Polyploidization increases the sensitivity to DNA-damaging agents in mammalian cells. FEBS letters. 2006 Aug 21;580(19):4727-36.
24. Wong C, Stearns T. Mammalian cells lack checkpoints for tetraploidy, aberrant centrosome number, and cytokinesis failure. BMC cell biology. 2005;6(1):6.
25. Gao P, Zheng J. Oncogenic virus-mediated cell fusion: new insights into initiation and progression of oncogenic viruses--related cancers. Cancer letters. 2011 Apr 1;303(1):1-8.
26. Duelli D, Lazebnik Y. Cell-to-cell fusion as a link between viruses and cancer. Nature reviews Cancer. 2007 Dec;7(12):968-76.
27. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature. 2009;460(7252):278-82.
28. Yang Z, Lončarek J, Khodjakov A, Rieder CL. Extra centrosomes and/or chromosomes prolong mitosis in human cells. Nature cell biology. 2008;10(6):748-51.
29. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495-7.
30. Olsson L, Kronstrom H, Cambon-De Mouzon A, Honzik C, Brodin T, Jakobsen B. Antibody producing human-human hybridomas. I. Technical aspects. Journal of Immunological methods. 1983;61(1):17-32.
31. Ebeling SB, Bos HMK, Slater R, Overkamp WJI, Cuthbert AP, Newbold RF, Zdzienicka MZ, Aarden LA. Human chromosome 21 determines growth factor dependence in human/mouse B-cell hybridomas. Cancer research. 1998;58(13):2863-8.
32. Dalm MCF, Jansen M, Keijzer TMP, van Grunsven WMJ, Oudshoorn A, Tramper J, Martens DE. Stable hybridoma cultivation in a pilot - scale acoustic perfusion system: Long - term process performance and effect of recirculation rate. Biotechnology and bioengineering. 2005;91(7):894-900.
33. Dewar V, Voet P, Denamur F, Smal J. Industrial implementation of in vitro production of monoclonal antibodies. ILAR JOURNAL. 2005;46(3):307.
34. Mable BK, Otto SP. Masking and purging mutations following EMS treatment in haploid, diploid and tetraploid yeast (*Saccharomyces cerevisiae*). Genetical research. 2001;77(01):9-26.
35. Levine DS, Sanchez CA, Rabinovitch PS, Reid BJ. Formation of the tetraploid intermediate is associated with the development of cells with more than four centrioles in the elastase-simian virus 40 tumor antigen transgenic mouse model of pancreatic cancer. Proceedings of the National Academy of Sciences. 1991;88(15):6427.
36. Nigg EA. Centrosome aberrations: cause or consequence of cancer progression? Nature Reviews Cancer. 2002;2(11):815-25.
37. Vitale I, Senovilla L, Jemaà M, Michaud M, Galluzzi L, Kepp O, Nanty L, Criollo A, Rello-Varona S, Manic G. Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos. The EMBO journal. 2010;29(7):1272-84.
38. Grompe M. The role of bone marrow stem cells in liver regeneration. Seminars in liver disease. 2003 Nov;23(4):363-72.
39. Vassilopoulos G, Wang PR, Russell DW. Transplanted bone marrow regenerates liver by cell fusion. Nature. 2003;422(6934):901-4.

40. Duncan AW, Hickey RD, Paulk NK, Culbertson AJ, Olson SB, Finegold MJ, Grompe M. Ploidy reductions in murine fusion-derived hepatocytes. *PLoS genetics*. 2009;5(2):e1000385.
41. Duncan AW, Taylor MH, Hickey RD, Newell AEH, Lenzi ML, Olson SB, Finegold MJ, Grompe M. The ploidy conveyor of mature hepatocytes as a source of genetic variation. *Nature*. 2010;467(7316):707-10.
42. Gupta S, editor. *Hepatic polyploidy and liver growth control* 2000: Elsevier.
43. Oberringer M, Lothschütz D, Jennewein M, Koschnick M, Mutschler W, Hanselmann RG. Centrosome multiplication accompanies a transient clustering of polyploid cells during tissue repair. *Molecular Cell Biology Research Communications*. 1999;2(3):190-6.
44. Storchova Z, Pellman D. From polyploidy to aneuploidy, genome instability and cancer. *Nature Reviews Molecular Cell Biology*. 2004;5(1):45-54.
45. Gurdon J, Melton D. Nuclear reprogramming in cells. *Science*. 2008;322(5909):1811.
46. Lin HP, Ogle BM. Nuclear Reprogramming. *Encyclopedia for Stem Cell Research*. CA: Sage Publications; 2008. p. 369-99.
47. Wilmut I, Schnieke A, McWhir J, Kind A, Campbell K. Viable offspring derived from fetal and adult mammalian cells. *Clones and clones: facts and fantasies about human cloning*. 1999:21.
48. Blau HM, Chiu CP, Webster C. Cytoplasmic activation of human nuclear genes in stable heterocaryons. *Cell*. 1983;32(4):1171-80.
49. Davidson RL, Ephrussi B, Yamamoto K. Regulation of pigment synthesis in mammalian cells, as studied by somatic hybridization. *Proceedings of the National Academy of Sciences of the United States of America*. 1966;56(5):1437.
50. Tada M, Tada T, Lefebvre L, Barton SC, Surani MA. Embryonic germ cells induce epigenetic reprogramming of somatic nucleus in hybrid cells. *The EMBO journal*. 1997;16(21):6510-20.
51. Yamanaka S, Blau HM. Nuclear reprogramming to a pluripotent state by three approaches. *Nature*. 2010;465(7299):704-12.
52. Kimura H, Tada M, Nakatsuji N, Tada T. Histone code modifications on pluripotential nuclei of reprogrammed somatic cells. *Molecular and Cellular Biology*. 2004;24(13):5710.
53. Powell AE, Anderson EC, Davies PS, Silk AD, Pelz C, Impey S, Wong MH. Fusion between intestinal epithelial cells and macrophages in a cancer context results in nuclear reprogramming. *Cancer research*. 2011;71(4):1497.
54. Wolfe KH. Yesterday's polyploids and the mystery of diploidization. *Nature Reviews Genetics*. 2001;2(5):333-41.
55. Wendel JF. Genome evolution in polyploids. *Plant molecular biology*. 2000;42(1):225-49.
56. Chester M, Gallagher JP, Symonds VV, da Silva AVC, Mavrodiev EV, Leitch AR, Soltis PS, Soltis DE. Extensive chromosomal variation in a recently formed natural allopolyploid species, *Tragopogon miscellus* (Asteraceae). *Proceedings of the National Academy of Sciences*. 2012;109(4):1176-81.
57. Eldredge N, Gould SJ. Punctuated equilibria: an alternative to phyletic gradualism. *Models in paleobiology*. 1972;82:115.
58. Sagan L. On the origin of mitosing cells. *Journal of Theoretical Biology*. 1967;14(3):225-74, IN1-IN6.
59. Oren-Suissa M, Podbilewicz B. Cell fusion during development. *Trends in cell biology*. 2007;17(11):537-46.
60. Chen EH, Grote E, Mohler W, Vignery A. Cell-cell fusion. *FEBS letters*. 2007;581(11):2181-93.
61. Helming L, Gordon S. Molecular mediators of macrophage fusion. *Trends in cell biology*. 2009;19(10):514-22.
62. Shinn-Thomas JH, Mohler WA. Chapter five - New Insights into the Mechanisms and Roles of Cell-Cell Fusion. In: Kwang WJ, editor. *International Review of Cell and Molecular Biology*: Academic Press; 2011. p. 149-209.
63. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. *Nature*. 2003;423(6937):337-42.

64. Moreno JL, Mikhailenko I, Tondravi MM, Keegan AD. IL-4 promotes the formation of multinucleated giant cells from macrophage precursors by a STAT6-dependent, homotypic mechanism: contribution of E-cadherin. *Journal of leukocyte biology*. 2007;82(6):1542-53.
65. Yagi M, Ninomiya K, Fujita N, Suzuki T, Iwasaki R, Morita K, Hosogane N, Matsuo K, Toyama Y, Suda T. Induction of DC-STAMP by Alternative Activation and Downstream Signaling Mechanisms. *Journal of Bone and Mineral Research*. 2007;22(7):992-1001.
66. Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N, Morita K, Ninomiya K, Suzuki T, Miyamoto K. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. *The Journal of experimental medicine*. 2005;202(3):345.
67. Helming L, Tomasello E, Kyriakides TR, Martinez FO, Takai T, Gordon S, Vivier E. Essential role of DAP12 signaling in macrophage programming into a fusion-competent state. *Science signaling*. 2008;1(43):ra11.
68. Kyriakides TR, Foster MJ, Keeney GE, Tsai A, Giachelli CM, Clark-Lewis I, Rollins BJ, Bornstein P. The CC chemokine ligand, CCL2/MCP1, participates in macrophage fusion and foreign body giant cell formation. *The American journal of pathology*. 2004;165(6):2157.
69. Vignery A. Macrophage fusion: the making of osteoclasts and giant cells. *The Journal of experimental medicine*. 2005 Aug 1;202(3):337-40.
70. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. *Cell*. 2009;138(2):286-99.
71. Liu AY. Differential expression of cell surface molecules in prostate cancer cells. *Cancer research*. 2000;60(13):3429.
72. Baier P, Eggstein S, Wolff-Vorbeck G, Baumgartner U, Hopt U. Chemokines in human colorectal carcinoma. *Anticancer research*. 2005;25(5):3581.
73. Zijlmans HJ, Fleuren G, Baelde H, Eilers PHC, Kenter G, Gorter A. The absence of CCL2 expression in cervical carcinoma is associated with increased survival and loss of heterozygosity at 17q11.2. *The Journal of pathology*. 2006;208(4):507-17.
74. Pawelek JM, Chakraborty AK. The cancer cell-leukocyte fusion theory of metastasis. *Advances in cancer research*. 2008;101:397-444.
75. Aspod C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D, Marches F, Banchereau J, Palucka AK. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4⁺ T cells that facilitate tumor development. *The Journal of experimental medicine*. 2007;204(5):1037.
76. Sens KL, Zhang S, Jin P, Duan R, Zhang G, Luo F, Parachini L, Chen EH. An invasive podosome-like structure promotes fusion pore formation during myoblast fusion. *The Journal of cell biology*. 2010;191(5):1013.
77. Jay SM, Skokos E, Laiwalla F, Krady MM, Kyriakides TR. Foreign body giant cell formation is preceded by lamellipodia formation and can be attenuated by inhibition of Rac1 activation. *The American journal of pathology*. 2007;171(2):632.
78. Miyado K, Yamada G, Yamada S, Hasuwa H, Nakamura Y, Ryu F, Suzuki K, Kosai K, Inoue K, Ogura A. Requirement of CD9 on the egg plasma membrane for fertilization. *Science*. 2000;287(5451):321.
79. Kaji K, Oda S, Miyazaki S, Kudo A. Infertility of CD9-deficient mouse eggs is reversed by mouse CD9, human CD9, or mouse CD81; polyadenylated mRNA injection developed for molecular analysis of sperm-egg fusion. *Developmental biology*. 2002;247(2):327-34.
80. Jégou A, Ziyat A, Barraud-Lange V, Perez E, Wolf JP, Pincet F, Gourier C. CD9 tetraspanin generates fusion competent sites on the egg membrane for mammalian fertilization. *Proceedings of the National Academy of Sciences*. 2011;108(27):10946.
81. Okabe M, Adachi T, Takada K, Oda H, Yagasaki M, Kohama Y, Mimura T. Capacitation-related changes in antigen distribution on mouse sperm heads and its relation to fertilization rate in vitro. *Journal of reproductive immunology*. 1987;11(2):91-100.

82. Inoue N, Ikawa M, Isotani A, Okabe M. The immunoglobulin superfamily protein Izumo is required for sperm to fuse with eggs. *Nature*. 2005;434(7030):234-8.
83. Larsson LI, Bjerregaard B, Talts JF. Cell fusions in mammals. *Histochemistry and cell biology*. 2008;129(5):551-61.
84. Chen EH, Olson EN. Unveiling the mechanisms of cell-cell fusion. *Science*. 2005;308(5720):369.
85. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature*. 1975 Aug 7;256(5517):495-7.
86. Hu L, Plafker K, Vorozhko V, Zuna RE, Hanigan MH, Gorbsky GJ, Plafker SM, Angeletti PC, Ceresa BP. Human papillomavirus 16 E5 induces bi-nucleated cell formation by cell-cell fusion. *Virology*. 2009;384(1):125-34.
87. Iessi E, Marino ML, Lozupone F, Fais S, De Milito A. Tumor acidity and malignancy: novel aspects in the design of anti-tumor therapy. *Cancer Therapy*. 2008;6:55-66.
88. Storchova Z, Kuffer C. The consequences of tetraploidy and aneuploidy. *Journal of cell science*. 2008;121(23):3859.
89. Hansemann D. Ueber asymmetrische Zelltheilung in Epithelkrebsen und deren biologische Bedeutung. *Virchows Archiv*. 1890;119(2):299-326.
90. Storchová Z, Breneman A, Cande J, Dunn J, Burbank K, O'Toole E, Pellman D. Genome-wide genetic analysis of polyploidy in yeast. *Nature*. 2006;443(7111):541-7.
91. Lu X, Kang Y. Cell fusion as a hidden force in tumor progression. *Cancer research*. 2009;69(22):8536.
92. Rajagopalan H, Lengauer C. Aneuploidy and cancer. *Nature*. 2004;432(7015):338-41.
93. Barrett MT, Pritchard D, Palanca-Wessels C, Anderson J, Reid BJ, Rabinovitch PS. Molecular phenotype of spontaneously arising 4N (G2-tetraploid) intermediates of neoplastic progression in Barrett's esophagus. *Cancer research*. 2003;63(14):4211.
94. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. *The American journal of gastroenterology*. 2001;96(11):3071-83.
95. Olaharski AJ, Sotelo R, Solorza-Luna G, Gonshebb ME, Guzman P, Mohar A, Eastmond DA. Tetraploidy and chromosomal instability are early events during cervical carcinogenesis. *Carcinogenesis*. 2006;27(2):337-43.
96. Abou-Elhamd KEA, Habib TN. The flow cytometric analysis of premalignant and malignant lesions in head and neck squamous cell carcinoma. *Oral oncology*. 2007;43(4):366-72.
97. Dictor M, Fernö M, Baldetorp B. Flow cytometric DNA content in Kaposi's sarcoma by histologic stage. Comparison with angiosarcoma. *Analytical and quantitative cytology and histology/the International Academy of Cytology [and] American Society of Cytology*. 1991;13(3):201.
98. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. *Nature*. 2005;437(7061):1043-7.
99. Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, Scudiero DA, Weinstein JN, Kirsch IR. Karyotypic complexity of the NCI-60 drug-screening panel. *Cancer research*. 2003;63(24):8634.
100. Abdel-Rahman WM, Katsura K, Rens W, Gorman PA, Sheer D, Bicknell D, Bodmer WF, Arends MJ, Wyllie AH, Edwards PAW. Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement. *Proceedings of the National Academy of Sciences*. 2001;98(5):2538.
101. Sirivatanauskorn V, Sirivatanauskorn Y, Gorman PA, Davidson JM, Sheer D, Moore PS, Scarpa A, Edwards PAW, Lemoine NR. Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping. *International Journal of Cancer*. 2001;91(3):350-8.
102. Davidson J, Gorringer K, Chin S, Orsetti B, Besret C, Courtay-Cahen C, Roberts I, Theillet C, Caldas C, Edwards P. Molecular cytogenetic analysis of breast cancer cell lines. *British journal of cancer*. 2000;83(10):1309.

103. Wistuba II, Bryant D, Behrens C, Milchgrub S, Virmani AK, Ashfaq R, Minna JD, Gazdar AF. Comparison of features of human lung cancer cell lines and their corresponding tumors. *Clinical cancer research*. 1999;5(5):991-1000.
104. Andreassen PR, Lohez OD, Lacroix FB, Margolis RL. Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. *Molecular biology of the cell*. 2001;12(5):1315-28.
105. Margolis RL, Lohez OD, Andreassen PR. G1 tetraploidy checkpoint and the suppression of tumorigenesis. *Journal of cellular biochemistry*. 2003;88(4):673-83.
106. Uetake Y, Sluder G. Cell cycle progression after cleavage failure. *The Journal of cell biology*. 2004;165(5):609.
107. Duelli DM, Hearn S, Myers MP, Lazebnik Y. A primate virus generates transformed human cells by fusion. *The Journal of cell biology*. 2005;171(3):493-503.
108. Duelli DM, Padilla-Nash HM, Berman D, Murphy KM, Ried T, Lazebnik Y. A virus causes cancer by inducing massive chromosomal instability through cell fusion. *Current biology : CB*. 2007 Mar 6;17(5):431-7.
109. Greenberg R. Telomeres, crisis and cancer. *Current molecular medicine*. 2005;5(2):213-8.
110. Chin K, de Solorzano CO, Knowles D, Jones A, Chou W, Rodriguez EG, Kuo WL, Ljung BM, Chew K, Myambo K. In situ analyses of genome instability in breast cancer. *Nature genetics*. 2004;36(9):984-8.
111. Lin TT, Letsolo BT, Jones RE, Rowson J, Pratt G, Hewamana S, Fegan C, Pepper C, Baird DM. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. *Blood*. 2010;116(11):1899-907.
112. Stewénus Y, Gorunova L, Jonson T, Larsson N, Höglund M, Mandahl N, Mertens F, Mitelman F, Gisselsson D. Structural and numerical chromosome changes in colon cancer develop through telomere-mediated anaphase bridges, not through mitotic multipolarity. *Proceedings of the National Academy of Sciences of the United States of America*. 2005;102(15):5541.
113. Chan JY. A Clinical Overview of Centrosome Amplification in Human Cancers. *International journal of biological sciences*. 2011;7(8):1122.
114. Weaver BAA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW. Aneuploidy acts both oncogenically and as a tumor suppressor. *Cancer cell*. 2007;11(1):25-36.
115. Rao CV, Yang YM, Swamy MV, Liu T, Fang Y, Mahmood R, Jhanwar-Uniyal M, Dai W. Colonic tumorigenesis in BubR1+/-ApcMin/+ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability. *Proceedings of the National Academy of Sciences of the United States of America*. 2005;102(12):4365.
116. Sussan TE, Annan Yang FL, Ostrowski MC, Reeves RH. Trisomy represses ApcMin-mediated tumours in mouse models of Down's syndrome. *Nature*. 2008;451(7174):73-5.
117. Jeganathan K, Malureanu L, Baker DJ, Abraham SC, Van Deursen JM. Bub1 mediates cell death in response to chromosome missegregation and acts to suppress spontaneous tumorigenesis. *The Journal of cell biology*. 2007;179(2):255-67.
118. Wang Z, Yu R, Melmed S. Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. *Molecular Endocrinology*. 2001;15(11):1870-9.
119. Yu R, Lu W, Chen J, McCabe CJ, Melmed S. Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. *Endocrinology*. 2003;144(11):4991-8.
120. Chesnokova V, Kovacs K, Castro AV, Zonis S, Melmed S. Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. *Molecular Endocrinology*. 2005;19(9):2371-9.
121. Donangelo I, Gutman S, Horvath E, Kovacs K, Wawrowsky K, Mount M, Melmed S. Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. *Endocrinology*. 2006;147(10):4781-91.
122. Yang Q, Rasmussen SA, Friedman J. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. *The Lancet*. 2002;359(9311):1019-25.

123. Satge D, Sommelet D, Geneix A, Nishi M, Malet P, Vekemans M. A tumor profile in Down syndrome. *American journal of medical genetics*. 1998;78(3):207-16.
124. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. *The Lancet*. 2000;355(9199):165-9.
125. Stanbridge EJ. Suppression of malignancy in human cells. *Nature*. 1976;260(5546):17.
126. Harris H, Miller O, Klein G, Worst P, Tachibana T. Suppression of malignancy by cell fusion. *Nature*. 1969;223(5204):363.
127. Anderson M, Stanbridge E. Tumor suppressor genes studied by cell hybridization and chromosome transfer. *The FASEB journal*. 1993;7(10):826.
128. Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations and gene fusions in cancer. 2011.
129. Kuukasjärvi T, Karhu R, Tanner M, Kähkönen M, Schäffer A, Nupponen N, Pennanen S, Kallioniemi A, Kallioniemi OP, Isola J. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. *Cancer research*. 1997;57(8):1597-604.
130. Waldman FM, DeVries S, Chew KL, Moore II DH, Kerlikowske K, Ljung BM. Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. *Journal of the National Cancer Institute*. 2000;92(4):313-20.
131. Hunter KW, Crawford N, Alsarraj J. Mechanisms of metastasis. *Breast Cancer Res*. 2008;10(Suppl 1):S2.
132. Lazebnik Y. What are the hallmarks of cancer? *Nature Reviews Cancer*. 2010;10(4):232-3.
133. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144(5):646-74.
134. Klein CA. Parallel progression of primary tumours and metastases. *Nature Reviews Cancer*. 2009;9(4):302-12.
135. Katoh M, Neumaier M, Nezam R, Izbicki J, Schumacher U. Correlation of circulating tumor cells with tumor size and metastatic load in a spontaneous lung metastasis model. *Anticancer research*. 2004;24(3A):1421-6.
136. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL. Genome remodelling in a basal-like breast cancer metastasis and xenograft. *Nature*. 2010;464(7291):999-1005.
137. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. *Journal of clinical oncology*. 1994;12(6):1272-80.
138. Van de Wouw A, Janssen-Heijnen M, Coebergh J, Hillen H. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992. *European Journal of Cancer*. 2002;38(3):409-13.
139. Friberg S, Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. *Journal of surgical oncology*. 1997;65(4):284-97.
140. Peer PGM, Van Dijck JAAM, Verbeek ALM, Hendriks JHCL, Holland R. Age - dependent growth rate of primary breast cancer. *Cancer*. 1993;71(11):3547-51.
141. Parris GE. Clinically significant cancer evolves from transient mutated and/or aneuploid neoplasia by cell fusion to form unstable syncytia that give rise to ecologically viable parasite species. *Medical hypotheses*. 2005;65(5):846-50.
142. Duesberg P, Fabarius A, Hehlmann R. Aneuploidy, the primary cause of the multilateral genomic instability of neoplastic and preneoplastic cells. *IUBMB life*. 2004;56(2):65-81.
143. Muller H. The relation of recombination to mutational advance. *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*. 1964;1(1):2-9.
144. Risques RA, Moreno V, Ribas M, Marcuello E, Capellà G, Peinado MA. Genetic pathways and genome-wide determinants of clinical outcome in colorectal cancer. *Cancer research*. 2003;63(21):7206.

145. Staibano S, Franco R, Mezza E, Chieffi P, Sinisi A, Pasquali D, Errico M, Nappi C, Tremolattera F, Somma P. Loss of oestrogen receptor β , high PCNA and p53 expression and aneuploidy as markers of worse prognosis in ovarian granulosa cell tumours. *Histopathology*. 2003;43(3):254-62.
146. Choma D, Daures J, Quantin X, Pujol J. Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data. *British journal of cancer*. 2001;85(1):14.
147. Southern JF, Warshaw AL, Lewandrowski KB. DNA ploidy analysis of mucinous cystic tumors of the pancreas: correlation of aneuploidy with malignancy and poor prognosis. *Cancer*. 1996;77(1):58-62.
148. Vinogradov A, Anatskaya O, Kudryavtsev B. Relationship of hepatocyte ploidy levels with body size and growth rate in mammals. *Genome*. 2001;44(3):350-60.
149. Brodsky VY, Delone G. Functional control of hepatocyte proliferation. Comparison with the temporal control of cardiomyocyte proliferation. *Biomedical science*. 1990;1(5):467.
150. Torres S, Díaz BP, Cabrera JJ, Díaz-Chico JC, Díaz-Chico BN, López-Guerra A. Thyroid hormone regulation of rat hepatocyte proliferation and polyploidization. *American Journal of Physiology-Gastrointestinal and Liver Physiology*. 1999;276(1):G155-G63.
151. Klein PA, Xiang J, Kimura AK. Melanoma cells growing in aggregates on a non-adhesive poly (HEMA) substrate exhibit polykaryocytosis but do not develop an increased metastatic capability. *Clinical and Experimental Metastasis*. 1984;2(4):287-95.
152. Lu X, Kang Y. Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants. *Proceedings of the National Academy of Sciences*. 2009;106(23):9385.
153. Goldenberg DM, Pavia RA, Tsao MC. In vivo hybridisation of human tumour and normal hamster cells. 1974.
154. Kerbel RS, Lagarde A, Dennis J, Donaghue T. Spontaneous fusion in vivo between normal host and tumor cells: possible contribution to tumor progression and metastasis studied with a lectin-resistant mutant tumor. *Molecular and Cellular Biology*. 1983;3(4):523.
155. Mortensen K, Lichtenberg J, Thomsen P, Larsson LI. Spontaneous fusion between cancer cells and endothelial cells. *Cellular and molecular life sciences*. 2004;61(16):2125-31.
156. Jacobsen BM, Harrell JC, Jedlicka P, Borges VF, Varella-Garcia M, Horwitz KB. Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium. *Cancer research*. 2006;66(16):8274.
157. Smith MA, Bidochka MJ. Bacterial fitness and plasmid loss: the importance of culture conditions and plasmid size. *Canadian journal of microbiology*. 1998;44(4):351-5.
158. Goldenberg DM, Zagzag D, Heselmeyer-Haddad KM, Berroa Garcia LY, Ried T, Loo M, Chang CH, Gold DV. Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivo. *International Journal of Cancer*. 2011.
159. Aichel O. Ueber Zellverschmelzung mit qualitativ abnormer Chromosomenverteilung als Ursache der Geschwulstbildung, von Prof. Dr. Med. Et phil. Otto Aichel: W. Engelmann; 1911.
160. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. *The New England journal of medicine*. 1986;315(26):1650.
161. Pollard JW. Trophic macrophages in development and disease. *Nature Reviews Immunology*. 2009;9(4):259-70.
162. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM. CD4⁺ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. *Cancer cell*. 2009;16(2):91-102.
163. Ribatti D, Crivellato E, Roccaro A, Ria R, Vacca A. Mast cell contribution to angiogenesis related to tumour progression. *Clinical & Experimental Allergy*. 2004;34(11):1660-4.
164. De Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. *Cancer cell*. 2005;7(5):411-23.

165. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. *New England Journal of Medicine*. 2004;351(21):2159-69.
166. Rizvi AZ, Swain JR, Davies PS, Bailey AS, Decker AD, Willenbring H, Grompe M, Fleming WH, Wong MH. Bone marrow-derived cells fuse with normal and transformed intestinal stem cells. *PNAS*. 2006;103(16):6321-5.
167. Johansson CB, Youssef S, Koleckar K, Holbrook C, Doyonnas R, Corbel SY, Steinman L, Rossi FMV, Blau HM. Extensive fusion of haematopoietic cells with Purkinje neurons in response to chronic inflammation. *Nature cell biology*. 2008;10(5):575-83.
168. Nygren JM, Liuba K, Breitbach M, Stott S, Thorén L, Roell W, Geisen C, Sasse P, Kirik D, Björklund A. Myeloid and lymphoid contribution to non-haematopoietic lineages through irradiation-induced heterotypic cell fusion. *Nature cell biology*. 2008;10(5):584-92.
169. Chakraborty A, Lazova R, Davies S, Bäckvall H, Ponten F, Brash D, Pawelek J. Donor DNA in a renal cell carcinoma metastasis from a bone marrow transplant recipient. *Bone marrow transplantation*. 2004;34(2):183-6.
170. Andersen TL, Boissy P, Sondergaard T, Kupisiewicz K, Plesner T, Rasmussen T, Haaber J, Kølvrå S, Delaissé J. Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer–host partnership? *The Journal of pathology*. 2007;211(1):10-7.
171. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. *Cell*. 2009;139(5):871-90.
172. Rachkovsky M, Pawelek J. Acquired melanocyte stimulating hormone-inducible chemotaxis following macrophage fusion with Cloudman S91 melanoma cells. *Cell growth & differentiation: the molecular biology journal of the American Association for Cancer Research*. 1999;10(7):517.
173. Sodi S, Chakraborty A, Platt J, Kolesnikova N, Rosembat S, KEH - YEN A, Bologna J, Rachkovsky M, Orlov S, Pawelek J. Melanoma× Macrophage Fusion Hybrids Acquire Increased Melanogenesis and Metastatic Potential: Altered N - Glycosylation as an Underlying Mechanism. *Pigment cell research*. 1998;11(5):299-309.
174. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. *Nature Reviews Cancer*. 2004;4(1):71-8.
175. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. *Cell*. 2006;124(2):263-6.
176. Bingle L, Brown N, Lewis C. The role of tumour - associated macrophages in tumour progression: implications for new anticancer therapies. *The Journal of pathology*. 2002;196(3):254-65.
177. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. *Journal of leukocyte biology*. 2008;84(3):623-30.
178. Chakraborty AK, Kolesnikova N, JdF S, Espreafico EM, Peronni KC, Pawelek J. Expression of c-Met Proto-oncogene in Metastatic Macrophage Melanoma Fusion Hybrids: Implication of Its Possible Role in MSH-Induced Motility. *Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics*. 2003;14(3):163-74.
179. Chakraborty AK, Pawelek J, Ikeda Y, Miyoshi E, Kolesnikova N, Funasaka Y, Ichihashi M, Taniguchi N. Fusion hybrids with macrophage and melanoma cells up-regulate N-acetylglucosaminyltransferase V, β 1-6 branching, and metastasis. *Cell growth and differentiation*. 2001;12(12):623-30.
180. Wright NA. Epithelial stem cell repertoire in the gut: clues to the origin of cell lineages, proliferative units and cancer. *International journal of experimental pathology*. 2000;81(2):117-43.
181. Holmgren L, Szeles A, Rajnavölgyi E, Folkman J, Klein G, Ernberg I, Falk KI. Horizontal transfer of DNA by the uptake of apoptotic bodies. *Blood*. 1999;93(11):3956.

182. Bergsmedh A, Szeles A, Henriksson M, Bratt A, Folkman MJ, Spetz AL, Holmgren L. Horizontal transfer of oncogenes by uptake of apoptotic bodies. *Proceedings of the National Academy of Sciences*. 2001;98(11):6407.
183. Al-Nedawi K, Meehan B, Rak J. Messengers and mediators of tumor progression. *Cell Cycle*. 2009;8(13):2014-8.
184. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. *Nature cell biology*. 2008;10(5):619-24.
185. Davis DM, Sowinski S. Membrane nanotubes: dynamic long-distance connections between animal cells. *Nature Reviews Molecular Cell Biology*. 2008;9(6):431-6.
186. Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides S, Chiavarina B, Bonuccelli G, Trimmer C, Tsigos A, Migneco G, Witkiewicz AK, Balliet R. The autophagic tumor stroma model of cancer or “battery-operated tumor growth”: A simple solution to the autophagy paradox. *Cell Cycle*. 2010;9(21):4297.
187. Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. *Advances in genetics*. 2005;54:1-20.
188. Christa N, Cornelia H, Kurt Z, Thomas D. Co-cultivation of murine BMDCs with 67NR mouse mammary carcinoma cells give rise to highly drug resistant cells. *Cancer Cell International*. 11.
189. Kerppola TK. Visualization of molecular interactions by fluorescence complementation. *Nature Reviews Molecular Cell Biology*. 2006;7(6):449-56.
190. Kerppola TK. Bimolecular fluorescence complementation: visualization of molecular interactions in living cells. *Methods in cell biology*. 2008;85:431-70.
191. Lin HP, Vincenz C, Eliceiri KW, Kerppola TK, Ogle BM. Bimolecular fluorescence complementation analysis of eukaryotic fusion products. *Biology of the Cell*. 2010;102(Pt 9):525.
192. Sprangers A, Freeman B, Kouris N, Ogle B. A Cre-Lox P Recombination Approach for the Detection of Cell Fusion In Vivo. *Journal of visualized experiments: JoVE*. 2012(59).
193. Kouris NA, Schaefer JA, Hatta M, Kawaoka Y, Kamp TJ, Ogle BM. Directed fusion of mesenchymal stem cells with cardiomyocytes via VSV-G facilitates stem cell programming. *Stem Cells International*. In Press 2012.